The Headlines
TRANSCEND-T2D-1 Top-Line Results — Retatrutide 12mg vs Placebo at 40 Weeks
On April 3, 2026, Eli Lilly announced that retatrutide met its primary endpoint in TRANSCEND-T2D-1 — a Phase 3 randomized controlled trial in adults with type 2 diabetes. The drug achieved superior HbA1C reduction compared to placebo across all three doses tested, and produced meaningful weight loss with no signs of plateauing at 40 weeks.
Trial Design
TRANSCEND-T2D-1 (NCT06354660) enrolled 537 adults with inadequate glycemic control on diet and exercise alone. Key baseline characteristics:
Mean baseline HbA1C: 7.9% — representing moderate to moderately severe uncontrolled type 2 diabetes. Mean BMI: 35.8 kg/m² — most participants had obesity alongside their diabetes. Mean T2D duration: 2.5 years — relatively early-stage disease. All retatrutide arms began at 2mg and escalated every 4 weeks to the target dose.
Participants were randomized 1:1:1:1 to retatrutide 4mg, 9mg, or 12mg, or placebo over 40 weeks.
Primary Endpoint — HbA1C Reduction
| Treatment Arm | HbA1C Reduction | vs Placebo | Primary Endpoint |
|---|---|---|---|
| Placebo | −0.8% | — | — |
| Retatrutide 4mg | −1.7% | −0.9% better | ✓ Met superiority |
| Retatrutide 9mg | −2.0% | −1.2% better | ✓ Met superiority |
| Retatrutide 12mg | −1.9% | −1.1% better | ✓ Met superiority |
All three doses met the primary endpoint of superior HbA1C reduction versus placebo. The 9mg dose achieved the greatest A1C reduction at −2.0%. For context, the current gold standard for T2D pharmacotherapy — tirzepatide — achieves approximately 2.0–2.3% A1C reduction in its Phase 3 trials. Retatrutide is directly competitive.
Key Secondary Endpoint — Weight Loss
The weight loss data is arguably the more striking result. The 12mg group lost an average of 36.6 lbs (16.8%) at 40 weeks — with no weight loss plateau observed through the end of the treatment period. This "no plateau" signal is particularly significant because it suggests weight loss would continue beyond 40 weeks with continued treatment.
| Treatment Arm | Weight Loss (lbs) | Weight Loss (%) | Plateau at 40 wks? |
|---|---|---|---|
| Placebo | ~3–4 lbs | ~1–2% | — |
| Retatrutide 4mg | ~18 lbs | ~8–9% | No |
| Retatrutide 9mg | ~28 lbs | ~12–13% | No |
| Retatrutide 12mg | 36.6 lbs | 16.8% | No — still declining |
Additional Secondary Endpoints
Beyond HbA1C and weight, retatrutide also produced clinically meaningful improvements across cardiovascular risk markers at 40 weeks:
Non-HDL cholesterol: Significant reduction across all doses — important for the cardiovascular risk profile of T2D patients who typically have dyslipidemia.
Triglycerides: Meaningful reduction, consistent with the glucagon receptor's role in hepatic lipid metabolism.
Systolic blood pressure: Clinically significant reduction — relevant for T2D patients where hypertension is a common comorbidity.
All three secondary cardiovascular endpoints were met, strengthening the argument for retatrutide as a comprehensive cardiometabolic agent rather than simply a weight loss or glucose-lowering drug.
How This Compares to Tirzepatide (Mounjaro) in T2D
Tirzepatide is the current FDA-approved standard for T2D + obesity pharmacotherapy (sold as Mounjaro for diabetes). Comparing the T2D trial data:
| Drug | Best HbA1C reduction | Best weight loss | Trial duration | FDA approved T2D? |
|---|---|---|---|---|
| Retatrutide 9mg | −2.0% | −16.8% (12mg) | 40 weeks | No — investigational |
| Tirzepatide 15mg | −2.3% | −14.7% | 40 weeks | Yes — Mounjaro |
| Semaglutide 1mg | −1.8% | ~−6% | 40 weeks | Yes — Ozempic |
Tirzepatide still edges out retatrutide slightly on HbA1C reduction (−2.3% vs −2.0%) but retatrutide produces meaningfully greater weight loss (16.8% vs 14.7%) at 40 weeks, with no plateau. Given that retatrutide's weight loss curve was still declining at 40 weeks, longer follow-up will likely show retatrutide surpassing tirzepatide on both endpoints.
What This Means for FDA Approval
TRANSCEND-T2D-1 is one of the most important data releases of 2026 for retatrutide's regulatory path. A positive Phase 3 T2D trial meeting all endpoints is precisely the data Eli Lilly needs to support a type 2 diabetes NDA filing — which historically gets FDA approval faster than obesity indications.
Eli Lilly's pattern with tirzepatide was instructive: Mounjaro received FDA approval for T2D in May 2022, about 7 months after the NDA filing. Zepbound (obesity) followed 18 months later. If retatrutide follows a similar path, a T2D NDA filing in late 2026 could yield a T2D approval in mid-2027, with an obesity approval following in 2028.
Notably, Polymarket prediction markets are now pricing FDA approval of retatrutide in 2026 at 27% — up from just 12% one month ago. While a 2026 approval remains unlikely given that no NDA has been filed, the rapid upward movement signals growing market confidence in the overall timeline.
The Bottom Line
TRANSCEND-T2D-1 is a clean, positive Phase 3 readout. Retatrutide met every primary and secondary endpoint in type 2 diabetes — validating its efficacy as a glucose-lowering agent alongside its already well-established weight loss profile.
The most compelling data point is the continued weight loss trajectory at 40 weeks with no plateau. If this holds in longer-duration trials, retatrutide may ultimately produce greater weight loss in T2D patients than any currently approved drug — including tirzepatide.
With 6 more TRIUMPH program readouts expected throughout 2026, the data picture is filling in rapidly. An NDA filing in late 2026 is looking increasingly realistic.
Related Pages
- →Retatrutide FDA approval timeline — updated with latest data
- →Complete TRIUMPH Phase 3 program overview
- →Retatrutide vs Mounjaro — updated comparison
- →Latest retatrutide news feed